PD39-02 RESULTS OF PHASE 1 CLINICAL TRIAL OF HIGH DOSES OF SELENO-L-METHIONINE (SLM) IN SEQUENTIAL COMBINATION WITH AXITINIB IN PREVIOUSLY TREATED AND RELAPSED CLEAR CELL RENAL CARCINOMA (CCRCC) PATIENTS

Yousef Zakharia,Rohan Garje,James B. Brown,Kenneth G. Nepple,Andrew M. Bellizzi,Jaime Bonner,Deborah Parr,Janelle B Born,Jessica C. Sieren,Jinha Park,Mohammad Milhem,Youcef M. Rustum

PD39-02 RESULTS OF PHASE 1 CLINICAL TRIAL OF HIGH DOSES OF SELENO-L-METHIONINE (SLM) IN SEQUENTIAL COMBINATION WITH AXITINIB IN PREVIOUSLY TREATED AND RELAPSED CLEAR CELL RENAL CARCINOMA (CCRCC) PATIENTS

2020

Yousef Zakharia
Rohan Garje
James B. Brown
Kenneth G. Nepple
Andrew M. Bellizzi
Jaime Bonner
Deborah Parr
Janelle B Born
Jessica C. Sieren
Jinha Park
Mohammad Milhem
Youcef M. Rustum

INTRODUCTION AND OBJECTIVE:The overexpression of hypoxia induced factor 1a/2a in ccRCC leads to up-regulation of vascular endothelial growth factor (VEGF) that results in increased angiogenesis, tu...

Keywords:

Phases of clinical research
Urology
high doses
Seleno-l-methionine
previously treated
Clear Cell Renal Carcinoma
Axitinib
sequential combination
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations